Spoken Alpha
Lucid Diagnostics Inc.
Lucid Diagnostics provides the EsoGuard Esophageal DNA Test and EsoCheck Cell Collection Device for early detection of esophageal precancer in patients with chronic heartburn.
Lucid Diagnostics Inc is a Healthcare company operating in Medical Devices with a $149.5M market cap.
LUCD missed consensus EPS by 0.6% in Q2 FY2026, reported Aug 12, 2026.
19 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for LUCD.
$ curl https://api.spokenalpha.com/v1/companies/LUCDFAQ
Spoken Alpha indexes LUCD's earnings call transcripts at https://spokenalpha.com/companies/LUCD. Each call links to attributed speakers and parsed analyst Q&A. Lucid Diagnostics Inc.'s own investor relations page is at https://ir.luciddx.com/.
Lucid Diagnostics Inc. (LUCD) held its most recent earnings call on 2026-08-13, covering fiscal Q2 2026.
Lucid Diagnostics Inc. (LUCD) operates in the Healthcare sector (Medical Devices industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.08 | $-0.05 | -60.0% | $1.5M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.07 | $-0.06 | -16.7% | $1.3M | — | — | EODHD |
| Q4 FY2025 | 2026-03-29 | $-0.10 | $-0.10 | -2.6% | $1.5M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.10 | $-0.09 | -11.1% | $1.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-0.10 | $-0.10 | 0.0% | $1.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-12 | $-0.16 | $-0.11 | -45.5% | $828.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-23 | $-0.19 | $-0.17 | -11.8% | $1.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.20 | $-0.18 | -11.1% | $1.2M | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.20 | $-0.18 | -11.1% | $976.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-0.40 | $-0.27 | -48.1% | $1.0M | — | — | EODHD |
| Q4 FY2023 | 2024-03-24 | $-0.23 | $-0.20 | -15.0% | $1.0M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.22 | $-0.22 | 0.0% | $783.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.23 | $-0.27 | +14.8% | $159.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.24 | $-0.30 | +20.0% | $446.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-12 | $-0.23 | $-0.38 | +39.5% | $112.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.28 | $-0.32 | +12.5% | $76.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.28 | $-0.28 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.23 | $-0.24 | +4.2% | $189.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-27 | $-0.32 | $-0.20 | -60.0% | $300.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-15 | $-0.49 | $-0.23 | -100.0% | $200.0K | — | — | EODHD |
Source: EODHD. LUCD reported actuals as published; sparse fields render as —.